Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01337089 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 660
- Enrollment target
NCT01337089 is a Phase 3 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 660 participants.
The verdict
NCT01337089, a Phase 3 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 660 participants
- Enrollment target
Study Summary
This was a six-month open-label extension (OLE) study to evaluate the safety of long-term nabiximols (Sativex®) therapy when used as an adjunctive treatment in participants with advanced cancer. The study provided continued availability of nabiximols to participants who completed a preceding Phase 3 study and new (de novo) participants.
Interventions
- DRUG Nabiximols
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2011-01-19 |
| Est. Completion | 2016-01-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01337089
The ClinicalTrials.gov registry entry for NCT01337089 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nabiximols is the first listed.
NCT01337089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01337089 about?
NCT01337089 is a clinical study titled "Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain". This was a six-month open-label extension (OLE) study to evaluate the safety of long-term nabiximols (Sativex®) therapy when used as an adjunctive treatment in participants with advanced cancer. The study provided continued availability of nabiximols to participants who completed a preceding Phase 3...
What is the current status of trial NCT01337089?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 660 participants. The study started on 2011-01-19. Estimated completion is 2016-01-27.
What interventions are being tested in trial NCT01337089?
The interventions under investigation include: Nabiximols (DRUG).
Who is sponsoring clinical trial NCT01337089?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.